companiesCompany
Shanghai Allist Pharmaceuticals
aka Allist, 艾力斯
Allist is the single-product lung cancer company behind furmonertinib, China's other third-generation EGFR pill, partnered with ArriVent for the rest of the world.
Overview
Furmonertinib (Ivesa) approved 2021 and first line 2022; exon 20 insertion programme licensed to ArriVent BioPharma (US) with the global FURVENT phase 3. Profitability on one drug shows the size of China's EGFR-mutant lung cancer market.
Headquarters
Shanghai, CN
Scorecard
All companies#103of 680 companies, score 26
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +15
1 approved, 0 in phase 3, 0 earlier, 1 targets, 59 registry studies. Formula on the scorecards page.
Type
biotech · 688578.SS
Stage
Public
Website
Founded
2004